4.7 Review

Cardiovascular Aging and Heart Failure JACC Review Topic of the Week

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 74, Issue 6, Pages 804-813

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2019.06.053

Keywords

aging; amyloidosis; comorbidities; heart failure; risk factors

Funding

  1. Amgen
  2. Bayer
  3. Boehringer Ingelheim
  4. Elpen
  5. Lilly
  6. Menarini
  7. Merck
  8. Novartis
  9. Sanofi
  10. Servier
  11. Vianex
  12. WinMedica
  13. National Institutes of Health
  14. Patient Centered Outcomes Research Institute
  15. European Union

Ask authors/readers for more resources

Heart failure (HF) is a clinical syndrome that usually develops in the elderly. Complex interactions of the cardiovascular aging process with risk factors (obesity, hypertension, and atherosclerosis), comorbidities (anemia, chronic kidney disease, diabetes, and so on), and disease modifiers (sex, genes, others) contribute to the development of HF phenotype and outcome. A conglomerate of cellular and molecular mechanisms underlies the effects of aging on cardiovascular function, the most important being excessive oxidative stress and chronic low-grade inflammation superimposed on the limited cardiac regeneration capacity. Notably, a sizeable percentage of elderly HF patients have cardiac amyloidosis, an HF precipitator. This review summarizes the current published data on the mechanisms of cardiovascular aging as they contribute to the development of HF phenotype and outcome. (C) 2019 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available